[
  {
    "ts": null,
    "headline": "Q4 Earnings: These Buy-Rated Stocks Crushed Expectations",
    "summary": "The 2025 Q4 earnings cycle keeps rolling along, with overall growth remaining strong. Specifically, these companies knocked it out of the park, with both also sporting a favorable Zacks Rank.",
    "url": "https://finnhub.io/api/news?id=9e7e8328a2f2799bf53567731c4915f0f8d6715e006109f0d4c9a807287b91e9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771537440,
      "headline": "Q4 Earnings: These Buy-Rated Stocks Crushed Expectations",
      "id": 139152766,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "CAH",
      "source": "Yahoo",
      "summary": "The 2025 Q4 earnings cycle keeps rolling along, with overall growth remaining strong. Specifically, these companies knocked it out of the park, with both also sporting a favorable Zacks Rank.",
      "url": "https://finnhub.io/api/news?id=9e7e8328a2f2799bf53567731c4915f0f8d6715e006109f0d4c9a807287b91e9"
    }
  },
  {
    "ts": null,
    "headline": "STAA Gains FDA Nod to Expand EVO ICL Age Indication to 60 Years",
    "summary": "STAAR Surgical jumps 8% after the FDA expands the EVO ICL age range to 21-60, backed by strong safety data and rising demand for LASIK alternatives.",
    "url": "https://finnhub.io/api/news?id=1d2a193dabb3cbaf2ac376f23d6290581b8c786c66815df6a3112d6939f1904d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771520880,
      "headline": "STAA Gains FDA Nod to Expand EVO ICL Age Indication to 60 Years",
      "id": 139151509,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "CAH",
      "source": "Yahoo",
      "summary": "STAAR Surgical jumps 8% after the FDA expands the EVO ICL age range to 21-60, backed by strong safety data and rising demand for LASIK alternatives.",
      "url": "https://finnhub.io/api/news?id=1d2a193dabb3cbaf2ac376f23d6290581b8c786c66815df6a3112d6939f1904d"
    }
  },
  {
    "ts": null,
    "headline": "Has Adlai Nortye Ltd. Sponsored ADR (ANL) Outpaced Other Medical Stocks This Year?",
    "summary": "Here is how Adlai Nortye Ltd. Sponsored ADR (ANL) and Cardinal Health (CAH) have performed compared to their sector so far this year.",
    "url": "https://finnhub.io/api/news?id=d5280876efd5cacf6115bdfe36b3a94663135dfe4b28a9b98d183c8849870576",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771512003,
      "headline": "Has Adlai Nortye Ltd. Sponsored ADR (ANL) Outpaced Other Medical Stocks This Year?",
      "id": 139150608,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "CAH",
      "source": "Yahoo",
      "summary": "Here is how Adlai Nortye Ltd. Sponsored ADR (ANL) and Cardinal Health (CAH) have performed compared to their sector so far this year.",
      "url": "https://finnhub.io/api/news?id=d5280876efd5cacf6115bdfe36b3a94663135dfe4b28a9b98d183c8849870576"
    }
  },
  {
    "ts": null,
    "headline": "Bio-Rad's Q4 Earnings Miss Estimates, Revenues Surpass, Stock Down",
    "summary": "BIO misses Q4 EPS estimates as margins shrank and shares slid 12%, despite revenue growth and a rebound in Clinical Diagnostics sales.",
    "url": "https://finnhub.io/api/news?id=d3f3104f6cdd83a2bc656fc4c482b8444f43448e250b218e444ae8578758f9f8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771507980,
      "headline": "Bio-Rad's Q4 Earnings Miss Estimates, Revenues Surpass, Stock Down",
      "id": 139149206,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "CAH",
      "source": "Yahoo",
      "summary": "BIO misses Q4 EPS estimates as margins shrank and shares slid 12%, despite revenue growth and a rebound in Clinical Diagnostics sales.",
      "url": "https://finnhub.io/api/news?id=d3f3104f6cdd83a2bc656fc4c482b8444f43448e250b218e444ae8578758f9f8"
    }
  },
  {
    "ts": null,
    "headline": "Exact Sciences Q4 Earnings Match Estimates, Revenues Beat, Stock Up",
    "summary": "EXAS posts Q4 revenue beat as Screening and Precision Oncology grow, margins expand, shares tick up and Abbott merger plans progress.",
    "url": "https://finnhub.io/api/news?id=7b52283941ed432ed460556c44f5e26599dd382a504e619e60ae4746e44b3437",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771506960,
      "headline": "Exact Sciences Q4 Earnings Match Estimates, Revenues Beat, Stock Up",
      "id": 139149207,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "CAH",
      "source": "Yahoo",
      "summary": "EXAS posts Q4 revenue beat as Screening and Precision Oncology grow, margins expand, shares tick up and Abbott merger plans progress.",
      "url": "https://finnhub.io/api/news?id=7b52283941ed432ed460556c44f5e26599dd382a504e619e60ae4746e44b3437"
    }
  },
  {
    "ts": null,
    "headline": "PODD Stock Up on Q4 Earnings & Revenue Beat, Margins Rise",
    "summary": "Insulet jumps after Q4 EPS and revenue beat, margin expansion and record Omnipod growth power a strong 2025 finish and upbeat 2026 outlook.",
    "url": "https://finnhub.io/api/news?id=2cf513552059e3e80ef729a4e85b58fd8826334a11bccf8793e7dee45ae52098",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771506540,
      "headline": "PODD Stock Up on Q4 Earnings & Revenue Beat, Margins Rise",
      "id": 139149208,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "CAH",
      "source": "Yahoo",
      "summary": "Insulet jumps after Q4 EPS and revenue beat, margin expansion and record Omnipod growth power a strong 2025 finish and upbeat 2026 outlook.",
      "url": "https://finnhub.io/api/news?id=2cf513552059e3e80ef729a4e85b58fd8826334a11bccf8793e7dee45ae52098"
    }
  },
  {
    "ts": null,
    "headline": "$3.8 Billion Negative Pressure Wound Therapy (NPWT) Devices Market Assessment, 2030 - Featuring Solventum, Smith+Nephew, Cardinal Health, Molnlycke Health Care, ConvaTec Group and Other Key Players",
    "summary": "Key opportunities in the NPWT devices market include the growing demand for advanced wound healing technologies, particularly in managing diabetic foot ulcers and surgical site infections Negative Pressure Wound Therapy (NPWT) Devices Market Negative Pressure Wound Therapy (NPWT) Devices Market Dublin, Feb. 19, 2026 (GLOBE NEWSWIRE) -- The \"Negative Pressure Wound Therapy (NPWT) Devices: Global Markets\" has been added to ResearchAndMarkets.com's offering. The global market for negative pressure",
    "url": "https://finnhub.io/api/news?id=7c8bd7db6ce38d1f1e8f145ffaadf6d0d8033e403ded6cba88644020f6fa9895",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771501680,
      "headline": "$3.8 Billion Negative Pressure Wound Therapy (NPWT) Devices Market Assessment, 2030 - Featuring Solventum, Smith+Nephew, Cardinal Health, Molnlycke Health Care, ConvaTec Group and Other Key Players",
      "id": 139145247,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "CAH",
      "source": "Yahoo",
      "summary": "Key opportunities in the NPWT devices market include the growing demand for advanced wound healing technologies, particularly in managing diabetic foot ulcers and surgical site infections Negative Pressure Wound Therapy (NPWT) Devices Market Negative Pressure Wound Therapy (NPWT) Devices Market Dublin, Feb. 19, 2026 (GLOBE NEWSWIRE) -- The \"Negative Pressure Wound Therapy (NPWT) Devices: Global Markets\" has been added to ResearchAndMarkets.com's offering. The global market for negative pressure",
      "url": "https://finnhub.io/api/news?id=7c8bd7db6ce38d1f1e8f145ffaadf6d0d8033e403ded6cba88644020f6fa9895"
    }
  }
]